Top broker tips Integral Diagnostics (ASX:IDX) share price to climb 22% from here

Here's why the Integral Diagnostics Ltd (ASX:IDX) share price could be going 22% higher from where it trades today…

| More on:

You鈥檙e reading a free article with opinions that may differ from The Motley Fool鈥檚 Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Integral Diagnostics Ltd (ASX: IDX) share price has been a positive performer on Tuesday.

In morning trade, the medical imaging service provider's shares are up 1.5% to $4.50.

This means the Integral Diagnostics share price is now up a solid 25% since this time last year.

Can the Integral Diagnostics share price go even higher?

Positively, one leading broker believes the Integral Diagnostics share price can still go a lot higher from here.

According to a recent note out of Goldman Sachs, its analysts have initiated coverage on the company with a buy rating and $5.50 price target.

Based on the current Integral Diagnostics share price, this implies potential upside of ~22% over the next 12 months.

And if you include the 2.5% dividend yield that the broker is forecasting, this potential return stretches to almost 25%.

Why is Goldman Sachs bullish on Integral Diagnostics?

Goldman believes the medical imaging service provider is a well-run business in an attractive industry.

It also notes that it has a relatively secure volume profile of mid to high single digit growth and a clear path for further growth through brownfield expansions and merger and acquisition activities.

In addition, Goldman feels Integral Diagnostics is well-positioned to benefit from a number of key drivers. These include:

"1) Aging population and increasing prevalence of chronic diseases underpin the long term sustainability of the industry's volume growth profile;

2) Steady increase in utilisation/vol. of MRI and CT as Australia's current levels still remain well below its developed market peers (c.-50%), and we see little impediment to the narrowing of that gap;

3) Positive mix shift to high-acuity modalities over the mid-term (MRI, CT and PET) as these services deliver higher quality clinical outcomes while also generating higher revenue/margin per service for IDX (CT and MRI revenue c.2-3x above industry avg);

4) Pricing tailwind from reintroduction of indexation at c.1.5% p.a for 90% of Medicare items (c.80% of benefits). Further upside risk for pricing should MRI & PET (20% of benefits) get reindexed;

5) Clear scope for growth via further brownfield expansion and M&A (consolidation of a fragmented industry), for which we see a long runway of opportunities in both areas."

All in all, Goldman expects this to lead to earnings growth of ~9% per annum through to FY 2023.

And with the Integral Diagnostics share price trading at 22x estimated FY 2021 earnings, it feels this is an undemanding valuation for its current growth profile.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Integral Diagnostics Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on 鈴革笍 ASX Shares

a woman wearing a close-sitting hat featuring wires and thick computer screen glasses clutches her computer monitor and looks shocked and disturbed as she reads old-fashioned computer text from the screen.
Technology Shares

Here's why ASX 200 tech shares (ASX:XTX) outperformed today

ASX tech shares have taken a turn for the better today.

Read more

Worker in hard hat looks puzzled with one hand on chin
Resources Shares

Why did the Rio Tinto share price (ASX:RIO) have such a lousy 2021?

We look at what happened to this ASX 200 mining giant's shares last year

Read more

a miner wearing a hard hat smiles as he stands in front of heavy earth moving equipment on a barren mine site.
Share Gainers

Here's why the Rumble Resources (ASX:RTR) share price is climbing 5%

The mineral explorer's share price is on the rise amid promising drill results.

Read more

share price high, all time record, record share price, highest, price rise, increase, up,
鈴革笍 ASX Shares

Here are the top 10 ASX 200 shares on Wednesday

Here are your top 10 biggest gainers in the ASX 200 on Wednesday.

Read more

comical investor reading documents and surrounded by calculators
鈴革笍 ASX Shares

The ASX reporting wrap-up: WiseTech, Bravura, Seven Group

Just what the investor ordered. Here鈥檚 a recap of the companies that reported on Wednesday...

Read more

Doctor performing an ultrasound on pregnant woman
鈴革笍 ASX Shares

The ASX reporting wrap-up: Ansell, Kogan, Nanosonics

Just what the investor ordered. Here鈥檚 a recap of the companies that reported on Tuesday...

Read more

blue arrows representing a rising share price ASX 200
鈴革笍 ASX Shares

Here are the top 10 ASX 200 shares on Tuesday

Here are your top 10 biggest gainers in the ASX 200 on Tuesday.

Read more

unhappy investor considering computer screen
Share Market News

The ASX reporting wrap-up: Charter Hall, Ampol, NIB Holdings

Just what the investor ordered. Here鈥檚 a recap of the companies that reported on Monday...

Read more